Tempus AI, Inc. (TEM) Q2 2025 Earnings Call Transcript

Tempus AI (TEM) reported a strong Q2 2025, with revenue surging 89.6% to $314.6 million, driven by 115% growth in Genomics and 35.7% in Data and Services, including significant contributions from the AstraZeneca Pathos deal. The company demonstrated sequential improvement in adjusted EBITDA, narrowing losses to $5.6 million and nearing breakeven, while raising full-year 2025 revenue guidance to $1.26 billion. Management highlighted robust oncology and hereditary testing volumes, market share gains, and strategic progress in foundational AI model development, though noted that significant revenue from its MRD portfolio and pure AI algorithms remains contingent on future reimbursement.

Analysis

Tempus AI demonstrated significant operational momentum in its Q2 2025 results, highlighted by an 89.6% year-over-year revenue increase to $314.6 million, substantially beating expectations. This growth was propelled by a 115% surge in Genomics revenue, fueled by accelerating oncology testing volume growth from 20% last quarter to 26%, and a notable 32% increase in hereditary testing. The Data and Services segment also posted strong results with 35.7% growth, led by a 41% increase in its data licensing business, benefiting from a major foundation model deal with AstraZeneca. The company showed impressive operating leverage, with gross profit rising 160% and the adjusted EBITDA loss narrowing sequentially to just $5.6 million from a prior $16 million loss. This progress supports the decision to raise full-year 2025 revenue guidance to $1.26 billion while maintaining a forecast for positive adjusted EBITDA of approximately $5 million for the year. The balance sheet was also fortified through a $750 million convertible note issuance, enhancing financial flexibility. While the core business is executing strongly, management noted that significant revenue from its Minimal Residual Disease (MRD) portfolio is gated pending reimbursement, which is anticipated by the end of 2025 but expected to be a more meaningful contributor in 2026.

Key Decisions for Investors

• Given the significant revenue beat, raised full-year guidance to $1.26 billion, and clear trajectory to adjusted EBITDA breakeven, investors should view this as strong validation of the company's growth-with-discipline strategy.
• Monitor progress on Minimal Residual Disease (MRD) test reimbursement, expected by year-end 2025, as this represents a significant, gated catalyst for volume and revenue acceleration in 2026 and beyond.
• Assess the long-term value of the Data and Insights segment, treating the AstraZeneca foundation model deal as a key proof point and watching for similar large-scale pharma partnerships as an indicator of sustained, high-margin growth.
• It is prudent to recognize that while core oncology and hereditary testing are driving current outperformance, the monetization of the high-potential MRD and standalone AI algorithm portfolios remains largely dependent on future reimbursement events.